ML192 is primarily used as a selective antagonist for the GPR139 receptor, making it a valuable tool in neuroscience and pharmacological research. It is employed to study the functional roles of GPR139 in neural pathways, particularly those associated with mood regulation, addiction, and motor control. Researchers use ML192 to investigate its potential effects on dopamine and serotonin systems, offering insights into novel treatments for psychiatric and neurological disorders such as depression, schizophrenia, and Parkinson’s disease. Due to its specificity, ML192 helps in validating GPR139 as a therapeutic target in early-stage drug development.